EUVIMEDEUVIMED entdecken
Metaanalyse

Meta-analysis of the Therapeutic Impact of Cannabinoids in Inflammatory Bowel Disease

Hansol Kang, Christopher J Schmoyer iD, Alexandra Weiss, James D Lewis

Inflammatory Bowel Diseases · 06.02.2025 · 31 (2) · 450-460

DOI: 10.1093/ibd/izae158 ↗

Kurz gefasst

Metaanalyse in der Zeitschrift Inflammatory Bowel Diseases, online erschienen am 28.08.2024. Verfasst von Hansol Kang und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA, USA. Hauptthemen laut MEDLINE: Cannabinoids, Colitis, Ulcerative, Crohn Disease, Inflammatory Bowel Diseases. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 35 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

With the increasing legalization of medical and recreational cannabis, patients and providers have growing interest in the role of cannabinoids in treating inflammatory bowel disease. Prior meta-analysis has shown inconclusive evidence for efficacy of cannabinoids. We sought to produce an up-to-date meta-analysis that pools new data to evaluate the therapeutic effects of cannabinoids in both Crohn’s disease (CD) and ulcerative colitis (UC).

Methods

PubMed, Embase, CENTRAL and CINAHL were queried for randomized-controlled trials evaluating the impact cannabinoids in CD or UC. Random effects modeling was used to compute pooled estimates of risk difference. Heterogeneity was assessed using I2.

Results

Eight studies, including 4 studies of CD, 3 studies of UC, and 1 study of both diseases met inclusion criteria. Among 5 studies of CD, a statistically significant decrease in clinical disease activity following intervention was observed (risk ratios [RR], −0.91; 95% CI, CI:1.54 to CI:0.28, I2 = 71.9%). Clinical disease activity in UC was not significantly lower in the pooled analysis (RR, −2.13; 95% CI, −4.80 to 0.55; I2 = 90.3%). Improvement in quality of life (QoL) was observed in both CD and UC combined (RR, 1.79; 95% CI, 0.92-0.2.66; I2 = 82.8%), as well as individually. No differences were observed in the analysis on endoscopic disease activity and inflammatory markers.

Conclusions

This meta-analysis of clinical trials suggests that cannabinoids are associated with improved quality of life in both CD and UC, as well as improved disease activity but not inflammation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CannabinoidsColitis, UlcerativeCrohn DiseaseInflammatory Bowel DiseasesHumansRandomized Controlled Trials as Topic

Stichwörter der Autor:innen

Crohn’s diseasecannabinoid derivativescannabisinflammatory bowel diseasemarijuanameta-analysisulcerative colitis

Substanzen

Cannabinoids

Autor:innen und Institutionen

  • Department of Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA, USA.
  • Division of Gastroenterology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.
  • Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.

ORCID-Profile: Christopher J Schmoyer

Zitieren

APA

Kang, H., Schmoyer, C. J., Weiss, A., & Lewis, J. D. (2025). Meta-analysis of the Therapeutic Impact of Cannabinoids in Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 31(2), 450-460. https://doi.org/10.1093/ibd/izae158

Vancouver

Kang H, Schmoyer CJ, Weiss A, Lewis JD. Meta-analysis of the Therapeutic Impact of Cannabinoids in Inflammatory Bowel Disease. Inflammatory Bowel Diseases. 2025;31(2):450-460. doi:10.1093/ibd/izae158

BibTeX
@article{Kang2025,
  author = {Kang, Hansol and Schmoyer, Christopher J and Weiss, Alexandra and Lewis, James D},
  title = {Meta-analysis of the Therapeutic Impact of Cannabinoids in Inflammatory Bowel Disease},
  journal = {Inflammatory Bowel Diseases},
  year = {2025},
  volume = {31},
  number = {2},
  pages = {450--460},
  doi = {10.1093/ibd/izae158}
}
Kostenlos starten →